Skip to main content

Research Repository

Advanced Search

Outputs (19)

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial (2021)
Journal Article
Hoskin, P., Popova, B., Schofield, O., Brammer, C., Robinson, M., Brunt, A. M., …Kirkwood, A. A. (2021). 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, 22(3), 332-340. https://doi.org/10.1016/S1470-2045%2820%2930686-0

BACKGROUND: The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4 Gy in two fractions (low-dose radiation). METHODS: FoRT (Follicular Radioth... Read More about 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.

Breast Cancer Management Guidelines During COVID-19 Pandemic (2020)
Journal Article
Gowda S, M., Katherine Kabeer, K., Jafferbhoy, S., Marla, S., Soumian, S., Misra, V., …Brunt, A. M. (2020). Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82, 251-258. https://doi.org/10.1007/s12262-020-02466-7

The coronavirus disease (COVID-19) pandemic in 2020 has brought about complex challenges in healthcare delivery. With the new rules of lockdown and social distancing and with resources diverted to the management of COVID-19, there are difficulties in... Read More about Breast Cancer Management Guidelines During COVID-19 Pandemic.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (2019)
Journal Article
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Murray Brunt, A., Nemsadze, G., …C. Turner, N. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5), 423 - 433. https://doi.org/10.1200/JCO.19.00368

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been assoc... Read More about Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer (2019)
Journal Article
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5(11), 1556 - 1556. https://doi.org/10.1001/jamaoncol.2019.2526

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating... Read More about Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer.

long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma (2019)
Journal Article
Hoskin, P., Kirkwood, A., Popova, B., Schofield, O., Brammer, C., Robinson, M., …Clifton-Hadley, L. (2019). long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematological Oncology, 37(S2), 219 - 220. https://doi.org/10.1002/hon.34_2630

Supplement article.

Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) (2018)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Haviland, J., Titley, J., Benstead, K., …Yarnold, J. (2018, December). Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Presented at 2018 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

Meeting abstract (Abstract GS4-05 from 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas).

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015) (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Algurafi, H., Alhasso, A., Bliss, P., …Yarnold, J. (2018). FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology - Biology - Physics, 102(5), 1603 -1604. https://doi.org/10.1016/j.ijrobp.2018.08.049

Conference abstract.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial (2018)
Journal Article
Velikova, G., Jane Williams, L., Willis, S., Michael Dixon, J., Loncaster, J., Hatton, M., …Yuille, F. (2018). Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, 19(11), 1516 - 1529. https://doi.org/10.1016/s1470-2045%2818%2930515-1

Background Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radio... Read More about Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., …Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.